"instanceType","rationale","versionIdentifier","uuid:ID","id"
"StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","0778e6b2-6090-4dc5-8916-f14e6cb9da75","StudyVersion_1"
